ZA201007559B - Factor ix conjugates with extended half-lives - Google Patents

Factor ix conjugates with extended half-lives

Info

Publication number
ZA201007559B
ZA201007559B ZA2010/07559A ZA201007559A ZA201007559B ZA 201007559 B ZA201007559 B ZA 201007559B ZA 2010/07559 A ZA2010/07559 A ZA 2010/07559A ZA 201007559 A ZA201007559 A ZA 201007559A ZA 201007559 B ZA201007559 B ZA 201007559B
Authority
ZA
South Africa
Prior art keywords
conjugates
lives
factor
extended half
extended
Prior art date
Application number
ZA2010/07559A
Other languages
English (en)
Inventor
William Henry
Original Assignee
Cantab Biopharmaceuticals Patents Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cantab Biopharmaceuticals Patents Ltd filed Critical Cantab Biopharmaceuticals Patents Ltd
Publication of ZA201007559B publication Critical patent/ZA201007559B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/644Coagulation factor IXa (3.4.21.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21022Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
ZA2010/07559A 2008-04-24 2010-10-22 Factor ix conjugates with extended half-lives ZA201007559B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4754408P 2008-04-24 2008-04-24
PCT/IB2009/005763 WO2009130602A2 (en) 2008-04-24 2009-04-24 Factor ix conjugates with extended half-lives

Publications (1)

Publication Number Publication Date
ZA201007559B true ZA201007559B (en) 2012-01-25

Family

ID=41171051

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2010/07559A ZA201007559B (en) 2008-04-24 2010-10-22 Factor ix conjugates with extended half-lives

Country Status (22)

Country Link
US (1) US20110183906A1 (enExample)
EP (1) EP2280734B1 (enExample)
JP (1) JP2011519833A (enExample)
KR (1) KR20110016440A (enExample)
CN (1) CN102046205A (enExample)
AU (1) AU2009239641B2 (enExample)
BR (1) BRPI0911350A2 (enExample)
CA (1) CA2722169A1 (enExample)
CO (1) CO6300965A2 (enExample)
CR (1) CR11763A (enExample)
DK (1) DK2280734T3 (enExample)
EC (1) ECSP10010632A (enExample)
ES (1) ES2466340T3 (enExample)
IL (1) IL208908A0 (enExample)
MX (1) MX2010011672A (enExample)
MY (1) MY158228A (enExample)
NI (1) NI201000177A (enExample)
NZ (1) NZ588854A (enExample)
RU (1) RU2496521C2 (enExample)
UA (1) UA101497C2 (enExample)
WO (1) WO2009130602A2 (enExample)
ZA (1) ZA201007559B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5876208B2 (ja) 2006-12-15 2016-03-02 バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated 延長されたinvivo半減期を有する第VIIa因子−(ポリ)シアル酸結合体
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
SG178141A1 (en) 2009-07-27 2012-03-29 Baxter Int Blood coagulation protein conjugates
JP5909755B2 (ja) 2009-07-27 2016-04-27 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
EP3093029A1 (en) 2009-07-27 2016-11-16 Baxalta GmbH Blood coagulation protein conjugates
AU2010284977A1 (en) * 2009-08-20 2012-03-29 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
GB201007357D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
NZ605348A (en) 2010-07-09 2015-01-30 Biogen Idec Hemophilia Inc Factor ix polypeptides and methods of use thereof
DK2654794T3 (da) 2010-12-22 2020-06-08 Baxalta GmbH Materialer og fremgangsmåder til konjugering af et vandopløseligt fedtsyrederivat til et protein
AU2012262428C1 (en) * 2011-05-27 2018-10-11 Takeda Pharmaceutical Company Limited Therapeutic proteins with increased half-life and methods of preparing same
EA033469B1 (ru) 2012-04-16 2019-10-31 Cantab Biopharmaceuticals Patents Ltd Подкожное введение конъюгатов факторов крови с полиэтиленгликолем
HK1204924A1 (en) * 2012-06-19 2015-12-11 Polytherics Limited Process for preparation of antibody conjugates and antibody conjugates
TWI810729B (zh) 2012-09-25 2023-08-01 美商百歐維拉提夫治療公司 Fix多肽的應用
WO2014144549A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor ix polypeptide formulations
AR099340A1 (es) * 2014-02-12 2016-07-13 Novo Nordisk As Conjugados del factor de coagulación ix
SG10201913735SA (en) 2014-03-24 2020-03-30 Bioverativ Therapeutics Inc Lyophilized factor ix formulations
GB2564389A (en) 2017-07-04 2019-01-16 Green Running Ltd A system and method for utility management

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
US5268275A (en) 1991-05-08 1993-12-07 The University Of North Carolina At Chapel Hill Vitamin K-dependent carboxylase
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
WO1999003496A1 (en) 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
WO2000054787A1 (en) 1999-03-16 2000-09-21 The Children's Hospital Of Philadelphia Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
PL206148B1 (pl) * 2000-02-11 2010-07-30 Bayer HealthCare LLCBayer HealthCare LLC Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego
AU2003300139B2 (en) * 2002-12-31 2008-08-28 Nektar Therapeutics Maleamic acid polymer derivatives and their bioconjugates
KR101025143B1 (ko) * 2002-12-31 2011-04-01 넥타르 테라퓨틱스 가수분해상으로 안정한 말레이미드-종결 중합체
MXPA05007348A (es) * 2003-01-06 2005-10-05 Nektar Therapeutics Al Corp Derivados de polimeros solubles en agua tiol-selectivos.
WO2006127896A2 (en) * 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
GB0316294D0 (en) * 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
DK1842920T4 (da) 2003-09-23 2017-08-21 Univ North Carolina Chapel Hill Celler der co-udtrykker K-vitaminreduktase og K-vitaminafhængigt protein, samt anvendelse deraf til at forbedre produktiviteten af det K-vitaminafhængige protein
WO2005033140A1 (ja) * 2003-09-30 2005-04-14 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute 高純度血液凝固ix因子調製物およびその精製方法
PT1673450E (pt) 2003-10-14 2010-05-11 Baxter Int Polipéptido de reciclagem de epóxido de vitamina k, vkorc1, um alvo terapêutico de cumarina e seus derivados
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
KR101100059B1 (ko) * 2004-06-30 2011-12-29 넥타르 테라퓨틱스 중합체­인자 ix 부분의 접합체
EP1819829A1 (en) 2004-12-08 2007-08-22 ICOS Corporation Recombinant method for making multimeric proteins
DK1853700T3 (da) 2005-02-28 2013-01-07 Baxter Int Rekombinant co-ekspression af vitamin-k-epoxid-reduktase-underenhed 1 til forbedring af vitamin-k-afhængig proteinekspression
CA2601574C (en) 2005-03-15 2014-12-02 University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin k-dependent proteins
CA2647314A1 (en) * 2006-03-31 2007-11-08 Baxter International Inc. Pegylated factor viii
RU2008145084A (ru) * 2006-05-24 2010-06-27 Ново Нордиск Хелс Кеа Аг (Ch) Аналоги фактора ix, имеющие пролонгированное время полужизни in vivo
JP5737821B2 (ja) * 2006-08-17 2015-06-17 一夫 大橋 血友病b治療剤及びその製造方法

Also Published As

Publication number Publication date
NI201000177A (es) 2011-08-29
MY158228A (en) 2016-09-15
KR20110016440A (ko) 2011-02-17
CN102046205A (zh) 2011-05-04
US20110183906A1 (en) 2011-07-28
CO6300965A2 (es) 2011-07-21
HK1151986A1 (en) 2012-02-17
ES2466340T3 (es) 2014-06-10
RU2496521C2 (ru) 2013-10-27
NZ588854A (en) 2011-12-22
CA2722169A1 (en) 2009-10-29
EP2280734B1 (en) 2014-02-26
AU2009239641B2 (en) 2013-11-07
EP2280734A2 (en) 2011-02-09
UA101497C2 (ru) 2013-04-10
ECSP10010632A (es) 2011-02-28
MX2010011672A (es) 2011-03-02
DK2280734T3 (da) 2014-05-26
IL208908A0 (en) 2011-01-31
CR11763A (es) 2011-04-26
WO2009130602A2 (en) 2009-10-29
WO2009130602A9 (en) 2010-04-22
BRPI0911350A2 (pt) 2017-12-05
AU2009239641A1 (en) 2009-10-29
JP2011519833A (ja) 2011-07-14
WO2009130602A3 (en) 2010-02-11
RU2010147813A (ru) 2012-05-27

Similar Documents

Publication Publication Date Title
IL208908A0 (en) Factor ix conjugates with extended half-lives
IL284184A (en) Oligosaccharide-protein conjugates
IL211180B (en) Attached polyethylene glycol and docetaxel
IL216719A0 (en) Pure-peg-lipid conjugates
EP2334209A4 (en) FILE HAVING HAND FASTENING HAIR Weaving
EP2437767A4 (en) PROLONGED HALF-LIFE MOLECULES AND USES THEREOF
IL212941A0 (en) Usirna complexes
GB0804803D0 (en) Mobile payments
EP2230452A4 (en) BURNER STRUCTURE
SI2252471T1 (sl) Svinčnik
IL206095A0 (en) Chemically modified factor ix
IL199718A0 (en) Peptide-complement conjugates
GB0900676D0 (en) Irons
GB0906023D0 (en) Insulin-Nanoparticle conjugates
GB0801988D0 (en) Nanoparticle conjugates
GB0815949D0 (en) Nanoparticle conjugates
GB0822679D0 (en) Tshirt with slogan
AU4333P (en) Bonmadpipa Argyranthemum frutescens
AU4511P (en) BONMADCINK Argyranthemum frutescens
AU4827P (en) BONMADMERLO Argyranthemum frutescens
AU4828P (en) BONMADWITIM Argyranthemum frutescens
AU4334P (en) Bonmadprose Argyranthemum frutescens
AU4332P (en) BONMADCREL Argyranthemum frutescens
GB0821076D0 (en) Modified linkers
GB0802978D0 (en) Modified linkers